PI3K

Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that catalyze the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) to generate the second messenger phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P₃). The production of PI(3,4,5)P₃ facilitates the recruitment and activation of pleckstrin homology (PH) domain–containing proteins at the plasma membrane, thereby initiating downstream signaling cascades essential for cellular proliferation, survival, and migration.

PI3Ks are divided into three major classes, among which Class I PI3Ks are most prominently implicated in cancer biology. Class I enzymes comprise four distinct catalytic isoforms: PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ.

Class IA PI3Ks, the subclass most commonly associated with oncogenic signaling, function as heterodimeric lipid kinases composed of a catalytic p110 subunit (p110α, p110β, or p110δ, encoded by PIK3CA, PIK3CB, and PIK3CD, respectively) and a regulatory p85 subunit.

The PI3K signaling pathway plays a central role in diverse biological processes, including cell cycle progression, cellular growth, survival, actin cytoskeletal rearrangement, migration, and intracellular vesicular trafficking.

Frequently Asked Questions
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate phosphatidylinositol lipids to regulate cell growth, survival, metabolism, and immune signaling. PI3K activation leads to downstream AKT and mTOR pathway signaling. Aberrant PI3K signaling is frequently observed in cancer due to PIK3CA mutations, PTEN loss, or receptor tyrosine kinase activation.
Class I PI3Ks include four catalytic isoforms: PI3Kα (PIK3CA) PI3Kβ (PIK3CB) PI3Kδ (PIK3CD) PI3Kγ (PIK3CG) PI3Kα and β are broadly expressed, while PI3Kδ and γ are enriched in leukocytes and play critical roles in immune regulation. Isoform selectivity is an important consideration in drug development due to toxicity and immune effects.
PI3K inhibitors can be classified as: Pan-PI3K inhibitors Isoform-selective inhibitors (α, β, δ, γ) Dual PI3K/mTOR inhibitors Irreversible inhibitors Selectivity influences therapeutic window and toxicity profile.
While PI3K inhibitors block upstream lipid kinase activity, mTOR inhibitors act downstream at the level of mTORC1 or mTORC2. Dual PI3K/mTOR inhibitors target both nodes of the pathway and may achieve broader pathway suppression.

Items 276-300 of 411

  • DS-7423
    Cat. No.
    A79710

    DS-7423

    DS-7423 is a potent dual inhibitor of PI3K and mTOR, exhibiting IC50 values of 15.6 nM for PI3Kα and 34.9 nM for mTOR. This compound demonstrates significant anti-tumor activity, making it a valuable tool for research into cancer biology and potential therapeutic strategies. Its ability to inhibit key signaling pathways involved in cell growth and survival positions DS-7423 as a promising candidate for further exploration in oncology studies.

    1 mg
    $95.00
    5 mg
    $245.00
    All 6 sizes
  • PI3K-IN-37
    Cat. No.
    A79712

    PI3K-IN-37

    PI3K-IN-37 is a potent inhibitor of the PI3K family, specifically targeting PI3K α, β, and δ isoforms with IC50 values of 6, 8, and 4 nM, respectively. Additionally, PI3K-IN-37 demonstrates strong inhibition of mTOR with an IC50 of 4 nM. This compound is valuable for research applications involving cancer biology, metabolic disorders, and signaling pathways related to cell growth and survival.

    1 mg
    $290.00
    5 mg
    $885.00
    All 5 sizes
  • PI3K-IN-22
    Cat. No.
    A79713

    PI3K-IN-22

    PI3K-IN-22 is a potent dual inhibitor of the PI3Kα and mTOR kinases, with IC50 values of 0.9 nM and 0.6 nM, respectively. This compound exhibits substantial biological activity, making it valuable for investigating the roles of these pathways in cancer research. PI3K-IN-22 can facilitate the study of tumor growth and response to therapy, contributing to the understanding of oncogenic signaling and potential treatment strategies.

    1 mg
    $195.00
    5 mg
    $1,790.00
    All 4 sizes
  • PKI-179 hydrochloride
    Cat. No.
    A79714

    PKI-179 hydrochloride

    PKI-179 hydrochloride is a potent dual inhibitor of the PI3K and mTOR signaling pathways, demonstrating IC50 values of 8 nM for PI3K-α, 24 nM for PI3K-β, 74 nM for PI3K-γ, 77 nM for PI3K-δ, and 0.42 nM for mTOR. This compound is effective against mutant variants E545K and H1047R, with IC50s of 14 nM and 11 nM, respectively. PKI-179 hydrochloride has been shown to exhibit significant anti-tumor activity in vivo, making it a valuable tool for cancer research and therapeutic development targeting PI3K/mTOR pathways.

    5 mg
    $205.00
    10 mg
    $335.00
    All 5 sizes
  • SN32976
    Cat. No.
    A79715

    SN32976

    SN32976 is a potent and selective inhibitor of class I phosphoinositide 3-kinases (PI3K) and mTOR, exhibiting IC50 values of 15.1 nM for PI3Kα, 461 nM for PI3Kβ, 110 nM for PI3Kγ, 134 nM for PI3Kδ, and 194 nM for mTOR. This compound demonstrates significant selectivity against a wide panel of 442 kinases. SN32976 is primarily utilized in cancer research, showcasing notable anticancer activity that makes it a valuable tool for studying PI3K/mTOR pathway modulation.

    1 mg
    $95.00
    5 mg
    $215.00
    All 7 sizes
  • PI3K/mTOR Inhibitor-13 sodium
    Cat. No.
    A79718

    PI3K/mTOR Inhibitor-13 sodium

    PI3K/mTOR Inhibitor-13 sodium is a dual inhibitor targeting phosphoinositide 3-kinase (PI3K) and mTOR kinase, demonstrating oral bioavailability. This compound exhibits significant biological activity in the modulation of cellular growth and metabolism, making it a valuable tool in research related to sexual dysfunction, solid tumors, and idiopathic pulmonary fibrosis (IPF). Its dual inhibition profile presents opportunities for therapeutic exploration in various disease contexts.

    5 mg
    $345.00
    10 mg
    $530.00
    All 5 sizes
  • PI3K-IN-18
    Cat. No.
    A79719

    PI3K-IN-18

    PI3K-IN-18 is a potent inhibitor of the PI3K/mTOR signaling pathway, selectively targeting PI3K-α and mTOR with IC50 values of 41 nM and 49 nM, respectively. This compound exhibits significant biological activity by disrupting key signaling processes involved in cell growth and proliferation. PI3K-IN-18 is valuable for research applications focused on cancer biology, metabolism, and therapeutic strategies targeting the PI3K/mTOR axis.

    0.5 mg
    $80.00
    1 mg
    $140.00
    All 4 sizes
  • PI3Kα/mTOR-IN-1
    Cat. No.
    A79722

    PI3Kα/mTOR-IN-1

    PI3Kα/mTOR-IN-1 is a selective dual inhibitor targeting PI3Kα and mTOR, exhibiting an IC50 of 7 nM for PI3Kα in cellular assays. It demonstrates Kis of 10.6 nM and 12.5 nM for mTOR and PI3Kα in cell-free assays, respectively. This compound is instrumental in studies related to cancer biology and signal transduction, making it valuable for research involving the modulation of PI3K/mTOR pathways.

    1 mg
    $315.00
    5 mg
    $635.00
    All 6 sizes
  • PI3K/mTOR Inhibitor-9
    Cat. No.
    A79724

    PI3K/mTOR Inhibitor-9

    PI3K/mTOR Inhibitor-9 is a potent inhibitor targeting both the PI3K and mTOR pathways, exhibiting IC50 values of 38 nM for mTOR (in phospho-S6 cellular assays) and 6.6 μM, 6.6 μM, and 0.8 μM for PI3Kα, PI3Kγ, and PI3Kδ, respectively. This compound demonstrates significant biological activity in modulating cellular growth and metabolism, making it a valuable tool for research on cancer and other diseases characterized by dysregulated PI3K/mTOR signaling. Its application in various cellular models facilitates the exploration of therapeutic strategies in oncology and other fields of biomedical research.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3K/mTOR Inhibitor-5
    Cat. No.
    A79728

    PI3K/mTOR Inhibitor-5

    PI3K/mTOR Inhibitor-5 selectively targets both phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), demonstrating IC50 values of 86.9 nM for PI3K and 14.6 nM for mTOR. This dual inhibition has significant implications for cancer research, as it can effectively impede cell proliferation and survival in tumor cells. PI3K/mTOR Inhibitor-5 is suitable for studies investigating the PI3K/mTOR signaling pathway and its role in various diseases, particularly in the contexts of oncology and metabolic disorders.

    25 mg
    $1,530.00
    50 mg
    $1,950.00
    All 3 sizes
  • PI3K/mTOR Inhibitor-3
    Cat. No.
    A79734

    PI3K/mTOR Inhibitor-3

    PI3K/mTOR Inhibitor-3 is a potent dual inhibitor of phosphoinositide 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR). This imidazoline derivative exhibits significant anti-cancer activity, making it a valuable tool for cancer research. Its ability to modulate key signaling pathways related to cell growth and survival enhances its utility in studying tumor biology and therapeutic strategies.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3Kα-IN-5
    Cat. No.
    A79735

    PI3Kα-IN-5

    PI3Kα-IN-5 is a potent inhibitor of the PI3Kα and mTOR pathways, exhibiting IC50 values of 0.7 nM and 3.3 nM, respectively. This compound is valuable for research focused on colorectal cancer, offering insights into the modulation of these critical signaling pathways. Its specificity and efficacy make it an important tool for investigating the roles of PI3Kα and mTOR in cancer biology.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3K/mTOR Inhibitor-12
    Cat. No.
    A79739

    PI3K/mTOR Inhibitor-12

    PI3K/mTOR Inhibitor-12 is a selective inhibitor targeting the phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) pathways, exhibiting IC50 values of 0.06 nM for PI3Kα and 3.12 nM for mTOR. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. Additionally, PI3K/mTOR Inhibitor-12 has been shown to possess reduced liver toxicity, enhancing its potential for therapeutic applications in oncology.

    25 mg
    $1,405.00
    50 mg
    $1,790.00
    All 3 sizes
  • PI3K/mTOR ligand-1
    Cat. No.
    A79740

    PI3K/mTOR ligand-1

    PI3K/mTOR ligand-1 is a ligand targeting the PI3K/mTOR pathway, crucial for cell growth and metabolism regulation. It functions as a building block for the synthesis of PROTACs aimed at modulating PI3K/mTOR signaling. This compound is valuable in cancer research and drug discovery efforts focusing on targeted protein degradation and pathway inhibition.

    25 mg
    $60.00
    50 mg
    $90.00
    All 3 sizes
  • PI3K/mTOR Inhibitor-8
    Cat. No.
    A79742

    PI3K/mTOR Inhibitor-8

    PI3K/mTOR Inhibitor-8 is a potent dual inhibitor of PI3K and mTOR, exhibiting IC50 values of 0.46 nM and 12 nM against PI3Kα and mTOR, respectively. This compound promotes apoptosis in HCT-116 cells and effectively induces cell cycle arrest at the G1/S phase. It serves as a valuable tool for researchers investigating the roles of PI3K and mTOR signaling in cancer biology and potential therapeutic interventions.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • MCX 28
    Cat. No.
    A79745

    MCX 28

    MCX 28 is a potent inhibitor of the phosphoinositide 3-kinase (PI3K) pathway, functioning as a triple inhibitor of PI3K, mTOR, and PIM kinases. It exhibits low nanomolar activity, making it a valuable tool for studying signaling pathways involved in cancer and other diseases. This compound is particularly useful for research applications focused on the modulation of cell proliferation, survival, and metabolic processes.

    5 mg
    $795.00
    All 1 sizes
  • PI3K/mTOR-IN-18
    Cat. No.
    A79748

    PI3K/mTOR-IN-18

    PI3K/mTOR-IN-18 is a highly selective dual inhibitor targeting PI3Kα and mTOR, with binding affinities of Ki=0.130 nM and Ki=0.111 nM, respectively. This compound effectively blocks the PI3K/AKT/mTOR signaling pathway, resulting in significant inhibition of tumor cell proliferation (IC50=144 nM). PI3K/mTOR-IN-18 is suitable for research involving various solid tumors, including breast cancer and non-small cell lung cancer (NSCLC).

    Out of stock

    All 3 sizes
  • PI3K/mTOR Inhibitor-14
    Cat. No.
    A79749

    PI3K/mTOR Inhibitor-14

    PI3K/mTOR Inhibitor-14 is a dual inhibitor targeting phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), exhibiting IC50 values of 171.4 nM and 10.1 nM, respectively. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. Its inhibition of the PI3K/mTOR signaling pathway can be critical for studies focused on cell proliferation and survival in various cancer models.

    Out of stock

    All 3 sizes
  • PI3K/mTOR Inhibitor-7
    Cat. No.
    A79750

    PI3K/mTOR Inhibitor-7

    PI3K/mTOR Inhibitor-7 (Compound 19i) is a potent dual inhibitor targeting the PI3K and mTOR pathways. It demonstrates a 4.7-fold increased potency compared to the positive control gedatolisib, with an IC50 of 0.3 μM. At a concentration of 10 μM, PI3K/mTOR Inhibitor-7 effectively suppresses the PI3K/Akt/mTOR signaling pathway. This compound is valuable for research applications focused on cancer biology and related therapeutic development.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3K/mTOR Inhibitor-6
    Cat. No.
    A79753

    PI3K/mTOR Inhibitor-6

    PI3K/mTOR Inhibitor-6 is a potent dual inhibitor targeting the phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) pathways. This compound demonstrates enhanced stability in artificial gastric fluids compared to other PI3K/mTOR inhibitors. At a concentration of 10 μM, PI3K/mTOR Inhibitor-6 effectively suppresses the PI3K/Akt/mTOR signaling pathway, highlighting its potential for cancer research applications.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI-540
    Cat. No.
    A79755

    PI-540

    PI-540 is a bicyclic thienopyrimidine derivative that functions as an orally active inhibitor of phosphoinositide 3-kinases (PI3K). Demonstrating potent anti-cancer cell proliferation activity, PI-540 selectively inhibits various PI3K isoforms with IC50 values of 10 nM for P110α, 3510 nM for P110β, 410 nM for P110δ, and 33110 nM for P110γ. In addition to its PI3K inhibition, PI-540 also targets mTOR and DNA-PK, with IC50 values of 61 nM and 525 nM, respectively, making it a valuable tool for cancer research and therapeutic development.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • CC-M-1
    Cat. No.
    A79756

    CC-M-1

    CC-M-1 is a potent and selective inhibitor of the PI3K/mTOR signaling pathway, targeting PI3Kα/β/γ/δ and mTOR with IC50 values of 0.68, 1.02, 1.03, 8.03, and 15 nM, respectively. This compound demonstrates significant inhibition of proliferation in colorectal cancer cell lines, including HCT-116 (IC50 = 0.38 μM) and HT-29 (IC50 = 1.70 μM). CC-M-1 serves as a valuable tool for researchers investigating colorectal cancer (CRC) therapeutic strategies and the underlying mechanisms of tumorigenesis.

    Out of stock

    All 3 sizes
  • PI3K/mTOR Inhibitor-13
    Cat. No.
    A79757

    PI3K/mTOR Inhibitor-13

    PI3K/mTOR Inhibitor-13 is a potent, orally active dual inhibitor targeting phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). This compound demonstrates significant biological activity against various pathologies, including solid tumors, sexual diseases, and idiopathic pulmonary fibrosis (IPF). It serves as a valuable tool for cancer research and therapeutic development related to these conditions.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • WJD008
    Cat. No.
    A79768

    WJD008

    WJD008 is a potent dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), specifically targeting PI3K α and mTOR kinase activities. It exhibits significant antiproliferative and anticlonogenic effects in tumor cells, particularly those with PIK3CA mutations. By disrupting the insulin-like growth factor-I-activated PI3K-Akt-mTOR signaling pathway, WJD008 holds promise for advancing cancer research and therapeutic strategies.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3K-IN-30
    Cat. No.
    A79783

    PI3K-IN-30

    PI3K-IN-30 is a selective inhibitor of phosphoinositide 3-kinases (PI3Ks), demonstrating potent inhibition with IC50 values of 5.1 nM for PI3Kα, 136 nM for PI3Kβ, 30.7 nM for PI3Kγ, and 8.9 nM for PI3Kδ. This compound is suitable for studies investigating PI3K signaling pathways and their implications in cancer and other diseases. Its high specificity and potency make it a valuable tool for biochemical and cellular research focused on PI3K-related mechanisms.

    2 mg
    $80.00
    5 mg
    $125.00
    All 6 sizes

Items 276-300 of 411

Added to your cart

View Cart Checkout

    Loading...